astria therapeutics glp-1 receptor agonist weight management diabetes treatments Advances in agonists delivery systems for obesity and Targeting GLP-1, GIP & GCG

Preliminary research suggests it may influence incretin hormone pathways, though clinical evidence supporting meaningful GLP-1 or GIP enhancement in humans is lacking

The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease

GLP-2: glucagon-like peptide-2

GLP-1RAs exert glycemic control through multiple mechanisms, including the stimulation of insulin secretion under hyperglycemic conditions, suppression of glucagon secretion during hyperglycemia, deceleration of gastric emptying to mitigate postprandial glucose spikes, reduction of caloric intake, and promotion of weight loss.71,8183 Short-acting GLP-1RAs, such as exenatide and lixisenatide, primarily reduce nocturnal and fasting glucose levels, while maintaining their effect on gastric emptying over prolonged treatment periods

Bastick, A